Legend Biotech Projects 2026 Operating Profit Amid Strong CARVYKTI® Growth and Pipeline Progress

summarizeResume

Legend Biotech's corporate presentation at the J.P. Morgan Healthcare Conference outlines a robust outlook, projecting company-wide operating profit in 2026. This financial milestone is supported by the strong commercial performance of CARVYKTI®, which has treated over 10,000 patients and achieved NCCN Category 1 designation. The company is also expanding manufacturing capacity and advancing its pipeline, including in vivo CAR-T studies and plans for new INDs, signaling continued innovation and growth.

check_boxEvenements cles

• Projected Profitability

  The company expects to achieve company-wide operating profit in 2026, marking a significant financial inflection point.

• CARVYKTI® Market Leadership

  CARVYKTI® has treated over 10,000 patients, achieved NCCN Category 1 designation, and boasts a 10,000 annualized dose capacity by 2026.

• Pipeline Advancement

  Patients have been dosed for IIT In Vivo CAR-T studies in 2025, with plans to file 1-2 US INDs in the second half of 2026.

• Manufacturing Scale-Up

  All CARVYKTI® manufacturing sites are now online, with a 97% success rate and a median turnaround time of less than 30 days.

auto_awesomeAnalyse

Legend Biotech's corporate presentation at the J.P. Morgan Healthcare Conference outlines a robust outlook, projecting company-wide operating profit in 2026. This financial milestone is supported by the strong commercial performance of CARVYKTI®, which has treated over 10,000 patients and achieved NCCN Category 1 designation. The company is also expanding manufacturing capacity and advancing its pipeline, including in vivo CAR-T studies and plans for new INDs, signaling continued innovation and growth.